Noerr advised Catalio Capital Management LP on investment in ATAI Life Sciences AG

Led by London partner Isabel Giancristofano our law firm advised Catalio Capital Management LP on its Series D minority investment in ATAI Life Sciences AG. The Series D financing round raised USD 157m in funding.

Catalio is a venture capital firm based in Baltimore, Maryland, USA, which specialises in investments in breakthrough biomedical technology companies.

Noerr previously advised on the Series C investment by Catalio in November 2020, which raised an aggregate of USD 125m.

ATAI Life Sciences is a German biotech company which develops psychedelic and non-psychedelic compounds for various mental health indications. ATAI Life Sciences will use the funds to work on its drug pipeline.

Other investors included Apeiron Investment Group, Thiel Capital, Woodline Partners, Fearless Ventures, Falcon Edge Capital, Pura Vida Pro LLC, Subversive Capital and Highline Capital.

Advisor Noerr

Corporate/M&A
Isabel Giancristofano, Thomas Schulz (London)

Capital Markets
Laurenz Wieneke (Frankfurt)